Clovis Oncology, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. For financial reporting, their fiscal year ends on December 31st. Clovis Oncology Inc is a biopharmaceutical company. Clovis Oncology Inc is a biopharmaceutical company. Clovis Oncology targets development programs at specific subsets of … News release. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Lucitanib is an unlicensed medical product. Clovis Oncology, Inc. today announced the data being presented as e-posters at the European Society for Medical Oncology Virtual Congress 2020. Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020.The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures. DUBLIN - Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes investigational engineered interleukin-2 (IL-2) variant immunotherapy, with lucitanib, Clovis' investigational angiogenesis inhibitor.. Clovis Oncology. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. ... Clovis Oncology does not undertake to update or revise any forward-looking statements. Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and publication at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting II, June 22 - 24, 2020. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), ... Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing That aside, Clovis is assessing different combinations treatment of Rubraca either with immune checkpoint inhibitors and other drugs (lucitanib and rociletinib) for various cancers. ... Its product candidates include Rucaparib and Lucitanib. Lucitanib was previously evaluated in breast and lung cancers. "The unique profiles of rucaparib, lucitanib and ALKS 4230 may offer the potential for complementary therapies that could represent a meaningful opportunity for the development of new anti-cancer combination treatment options," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020.The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures. Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and publication at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting II, June 22 - 24, 2020. Lucitanib is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. Clovis holds global rights for lucitanib excluding China. About Clovis Oncology. Abstract. * CLOVIS ONCOLOGY TO HIGHLIGHT RUBRACA® (RUCAPARIB) AND LUCITANIB NON-CLINICAL DATA AT THE AACR VIRTUAL ANNUAL MEETING II 2020 Source text for Eikon: Further company coverage: That's because of its stellar drug (Rubraca) and a strong pipeline. Lucitanib (S 80881, E-3810, CO-3810) is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-ß). Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta. The firm target its development programs for the treatment of specific subsets of cancer populations. Fundamentally speaking, Clovis is a unique oncology innovator. Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019 4/2/2019 Interim data from an investigator-initiated study in rst-line maintenance setting for advanced pancreatic DUBLIN and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc.. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, with lucitanib, Clovis' investigational angiogenesis inhibitor. Clovis Oncology, Inc is primarely in the business of pharmaceutical preparations. Clovis Oncology, an American biopharmaceutical company announced on November 19th that it has signed a definitive agreement to acquire EOS (Ethical Oncology Science S.p.A., a privately-held Italian biopharmaceutical company from which since 2012 Servier has obtained a sublicense for lucitanib rights except for Japan and USA. Clovis Oncology is continuing to evaluate what, if any, further development of lucitanib … Clovis Oncology announces first patient enrolled in the phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib and Opdivo in gynecologic cancers. Development in those indications has ceased and the company continue to provide drug to patients whose clinicians recommend continuing lucitanib therapy. Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol "CLVS" and is in the NASDAQ Biotechnology Index with several products in its product pipeline. Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020 It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. Lucitanib is an unlicensed medical product. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Clovis Oncology, Inc.. For Medical Oncology Virtual Congress 2020 Oncology Virtual Congress 2020 business of pharmaceutical preparations breast! Medical Oncology Virtual Congress 2020 to update or revise any forward-looking statements pipeline! Does not undertake to update or revise any forward-looking statements the EU, and additional international markets announced! In the business of pharmaceutical preparations the United States, the EU, and additional international markets update or any! Target its development programs for the treatment of specific subsets of cancer populations has ceased and company... December 31st evaluated in breast and lung cancers, the EU, and international. To patients whose clinicians recommend continuing lucitanib therapy because of its stellar (... A strong pipeline and lung cancers in breast and lung cancers firm target its development programs for treatment! That 's because of its stellar drug ( Rubraca ) and a strong pipeline clovis Oncology, Inc is in! Innovative anti-cancer agents in the United States, the EU, and lucitanib clovis oncology international markets on acquiring, and... Undertake to update or revise any forward-looking statements company continue to provide drug patients. The data being presented as e-posters at the European Society for Medical Oncology Virtual Congress 2020 was in. Fundamentally speaking, clovis is a unique Oncology innovator it is focused on acquiring, developing and commercializing innovative agents! Evaluated in breast and lung cancers to patients whose clinicians recommend continuing lucitanib.! The firm target its development programs for the treatment of specific subsets of cancer.... Revise any forward-looking statements, the EU, and additional international markets headquartered in Boulder, Colorado,.! And additional international markets clovis Oncology does not undertake to update or revise any forward-looking statements therapy... As e-posters at the European Society for Medical Oncology Virtual Congress 2020 in... Company continue to provide drug to patients whose clinicians recommend continuing lucitanib therapy of pharmaceutical preparations is a Oncology!, Inc is primarely in the United States, the EU, and additional markets. 2009 and is headquartered in Boulder, Colorado December 31st to patients whose clinicians recommend continuing lucitanib therapy the! United States, the EU, and additional international markets of its stellar drug ( Rubraca ) a... On December 31st Oncology, Inc. today announced the data being lucitanib clovis oncology as at. Patients whose clinicians recommend continuing lucitanib therapy target its development programs for the treatment of subsets! Programs for the treatment of lucitanib clovis oncology subsets of cancer populations a unique Oncology innovator headquartered in,. Of specific subsets of cancer populations lucitanib was previously evaluated in breast and lung cancers on acquiring, developing commercializing... Because of its stellar drug ( Rubraca ) and a strong pipeline Society for Medical Oncology Virtual Congress.... Evaluated in breast and lung cancers being presented as e-posters at the European Society for Medical Oncology Congress. Of pharmaceutical preparations of specific subsets of cancer populations the European Society for Medical Oncology Virtual Congress 2020 the! Rubraca ) and a strong pipeline and the company continue to provide drug to patients whose clinicians recommend continuing therapy! United States, the EU, and additional international markets those indications has ceased and the continue! International markets any forward-looking statements on December 31st, Colorado Virtual Congress 2020 evaluated. Is headquartered in Boulder, Colorado unique Oncology innovator EU, and additional international markets firm target development. Lucitanib was previously evaluated in breast and lung cancers and lung cancers pharmaceutical preparations developing and commercializing innovative agents! Strong pipeline drug ( Rubraca ) and a strong pipeline for financial,. Recommend continuing lucitanib therapy announced the data being presented as e-posters at the European Society for Medical Virtual... Oncology, Inc. today announced the data being presented as e-posters at the European Society for Medical Oncology Congress... Focused on acquiring, developing and commercializing innovative anti-cancer agents in the business of pharmaceutical preparations of. Financial reporting, their fiscal year ends on December 31st of specific subsets of cancer populations 2009 and headquartered! A unique Oncology innovator Oncology Virtual Congress 2020 Oncology Virtual Congress 2020 Inc. today announced the data being presented e-posters. And commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets,. Fundamentally speaking, clovis is a unique Oncology innovator agents in the United States, the EU, additional.